Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborator:
Incyte Biosciences International Sàrl
Studienleiter
Thorsten Goetze, Prof. Dr. Principal Investigator Krankenhaus Nordwest, Frankfurt Salah-Eddin Al-Batran, Prof. Dr. Study Director Institut für Klinische Krebsforschung IKF GmbH
Kontakt
Thorsten Goetze, Prof. Dr. Kontakt: Phone: +49 69 7601 4187 E-Mail: goetze.thorsten@khnw.de» Kontaktdaten anzeigen Doerthe Vortmeyer, Dr. Kontakt: Phone: +49 69 7601 4196 E-Mail: vortmeyer.doerthe@ikf-khnw.de» Kontaktdaten anzeigen
Studienlocations (3 von 4)
Charité - Universitätsmedizin Berlin 13353 Berlin (Berlin) GermanyRekrutierend» Google-Maps Ansprechpartner: Dominik Modest, Prof. Dr.» Ansprechpartner anzeigenInterdisziplinäres Brustzentrum am Klinikum Esslingen Hirschlandstraße 97 73730 Esslingen am Neckar (Baden-Württemberg) DeutschlandRekrutierend» Google-Maps Ansprechpartner: Henning Wege, Prof. Dr.» Ansprechpartner anzeigenOnkologisches Zentrum Krankenhaus Nordwest Steinbacher Hohl 2-26 60488 Frankfurt am Main DeutschlandRekrutierend» Google-Maps Ansprechpartner: Thorsten Goetze, Prof. Dr.» Ansprechpartner anzeigen
1. Objective response rate at time of progression (Time Frame - through study completion, approx. 3 years): Objective response rate according to investigator-based RECIST 1.1 assessment, defined as the proportion of allocated subjects with best response of complete or partial response within 12 months after the date of first administration of study treatment. Patients who receive anti-cancer treatment other than the study medication for any reason before reaching a complete or partial response will be identified as nonresponders in the assessment of ORR.
Secondary outcome:
1. Overall survival (Time Frame - up to 3 years): Overall survival until end of study
2. Quality of Life asssed by EORTC-QLQ-C30 with additional appendix BIL21 (Time Frame - from screening until end of study, approx. 3 years): Measurement of quality of life by questionaires filld in by the patients.
3. Incidence of treatment-related adverse events (Time Frame - from screening until end of study, approx. 3 years): Safety and tolerability will by measured by evaluation of incidence, treatment relationship, seriousness, and severity of all AEs, SAEs according to CTCAE V5.0.
Pemigatinib (Pemazyre): Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!